Supernus Pharmaceuticals (SUPN) Stock Price
Supernus Pharmaceuticals Price
Revenue has compounded at 28.3% per year over the past 19 years to 718.95 M USD. Earnings per share have grown at 27.8% per year over the last 15 years. Supernus Pharmaceuticals's net margin stands at -5.4%, down from 9.2% several years earlier. Analysts set a median price target of 65.00 USD, implying 69.1% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.
Supernus Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Supernus Pharmaceuticals business model & stock analysis
Frequently asked questions about Supernus Pharmaceuticals
The business model of Supernus Pharmaceuticals Inc revolves around the development and commercialization of innovative therapies for central nervous system (CNS) diseases. Supernus specializes in creating treatments that target epilepsy, attention deficit hyperactivity disorder (ADHD), and other CNS disorders. With a focus on research and development, Supernus aims to identify novel drug candidates, conduct clinical trials, and gain regulatory approvals for its products. By combining its expertise in neuroscience and pharmaceuticals, Supernus strives to improve the lives of patients suffering from neurologic and psychiatric conditions.
Supernus Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Supernus Pharmaceuticals Inc in the market are other pharmaceutical companies that specialize in the same therapeutic areas and products. Some of these competitors include companies like Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company. These companies also have a strong presence in the pharmaceutical industry and offer similar medications and treatments. However, Supernus Pharmaceuticals Inc differentiates itself through its unique product offerings and innovative research and development efforts.
Supernus Pharmaceuticals Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system diseases. Founded in 2005, Supernus has a strong history of success in bringing quality treatments to patients. Headquartered in Rockville, Maryland, the company has focused on researching and developing products for the treatment of epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological disorders. Supernus Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry, delivering innovative solutions for patients and healthcare professionals. With a dedication to improving patient lives, Supernus continues to make significant contributions to the medical field through its advanced therapies.
Supernus Pharmaceuticals Inc has achieved several significant milestones throughout its history. Notable achievements include the FDA approval of their flagship product, Trokendi XR, for the treatment of epilepsy and migraines. The company has also successfully launched Oxtellar XR, an antiepileptic drug, in the United States market. In addition, Supernus Pharmaceuticals Inc received FDA approval for Aptiom, an antiepileptic medication. These milestones demonstrate the company's commitment to developing innovative therapies and improving the quality of life for patients with neurological disorders. Supernus Pharmaceuticals Inc continues to focus on research and development, aiming to achieve more breakthroughs in the pharmaceutical industry.
Supernus Pharmaceuticals Inc is primarily present in the United States and has a strong presence in North America. With its headquarters located in Rockville, Maryland, the company has successfully expanded its operations, research, and development efforts within the region. Supernus Pharmaceuticals Inc focuses on developing and commercializing innovative therapies for various central nervous system diseases. Its dedication to improving patient's quality of life and commitment to scientific advancement has allowed the company to establish itself as a key player in the pharmaceutical industry in the US and North America.
Supernus Pharmaceuticals Inc represents values of innovation, patient-centricity, and integrity. The company is dedicated to developing and commercializing innovative therapies that address unmet medical needs. With a strong focus on neurology and psychiatry, Supernus Pharmaceuticals Inc strives to improve the lives of patients by providing effective and safe treatment options. Their corporate philosophy revolves around conducting business ethically and responsibly while maintaining transparent and collaborative relationships with healthcare professionals, patients, and stakeholders. Through their commitment to research and development, Supernus Pharmaceuticals Inc aims to make a positive impact on the healthcare industry and enhance patient well-being.
Analysts currently set an average price target of 65.00 USD for the Supernus Pharmaceuticals stock (median: 65.00 USD), implying +69.1 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Supernus Pharmaceuticals stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Supernus Pharmaceuticals to generate revenue of 877.71 M USD and earnings per share of 2.53 USD.
Converted at the current exchange rate, the Supernus Pharmaceuticals share trades at 34.24 EUR (38.43 USD).
The Supernus Pharmaceuticals share (SUPN) is listed on 7 stock exchanges, including: NASDAQ (SUPN), London (0LB2.L), SIX (Zürich) (S49.SW), Frankfurt (S49.F), München (S49.MU), Düsseldorf (S49.DU).
Supernus Pharmaceuticals Inc is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of central nervous system disorders. The company is headquartered in Rockville, Maryland, USA, and has offices in Canada and Europe. Supernus Pharmaceuticals Inc's business model is based on three core divisions: research and development, production, and distribution. The company aims to strengthen its research and development through strategic partnerships and acquisitions. Its product range includes a variety of drugs used to treat epilepsy, attention deficit/hyperactivity disorder (ADHD), and other drugs that affect the central nervous system. The main products of Supernus Pharmaceuticals Inc are the drugs Oxtellar XR and Trokendi XR, which are used to treat partial seizures in adults and children aged 6 and older. Oxtellar XR and Trokendi XR offer patients a once-daily dosage, increasing patient compliance and reducing the number of doses. Another important product of Supernus Pharmaceuticals Inc is Quillichew ER, used to treat ADHD in children. Quillichew ER is a once-daily chewable tablet, providing patients with a convenient way to take the medication. In addition to drug development and marketing, Supernus Pharmaceuticals Inc has also strengthened its production and distribution chain. The company owns a production facility in Montreal, Canada, and has an agreement with a company in Switzerland for drug manufacturing. The company has also entered into an agreement with a company to market Oxtellar XR, supporting sales efforts in Europe. Supernus Pharmaceuticals Inc directly distributes its products in the US and Canada. The company also has a distribution agreement with a company in Switzerland to distribute its products in Europe. In addition to drug development and marketing, Supernus Pharmaceuticals Inc operates a dedicated program to educate and support patients using its products. The company offers patient programs that provide support in medication compliance, disease management training, and access to special services and resources. Overall, Supernus Pharmaceuticals Inc has a strong business model based on the development and marketing of innovative drugs for the treatment of central nervous system disorders. The company aims to strengthen its research and development activities through strategic partnerships and acquisitions, and expand its presence internationally by strengthening its production and distribution chain. Supernus Pharmaceuticals Inc also remains committed to offering patient programs to support and care for patients using its products.
The expected revenue of Supernus Pharmaceuticals is 877.71 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Supernus Pharmaceuticals is 145.36 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Supernus Pharmaceuticals is currently 15.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Supernus Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Supernus Pharmaceuticals is currently 2.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Supernus Pharmaceuticals stock.
The Eulerpool Quality Score for Supernus Pharmaceuticals is 2/10.
The ISIN of Supernus Pharmaceuticals is US8684591089. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Supernus Pharmaceuticals is A1JX3U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Supernus Pharmaceuticals is SUPN. The ticker symbol is used to trade Supernus Pharmaceuticals shares on the stock exchange.
Supernus Pharmaceuticals stock
Supernus Pharmaceuticals Peer Group
Supernus Pharmaceuticals Ticker
Supernus Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Supernus Pharmaceuticals
Our stock analysis for Supernus Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Supernus Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.